Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|15|2603-2611

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.15, 2015-08, pp. : 2603-2611

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk of acute myocardial infarction after androgen‐deprivation therapy for prostate cancer in a Chinese population

By  

BJU INTERNATIONAL, Vol. 116, Iss. 3, 2015-09 ,pp. : 382-387

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of new‐onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population 亚洲前列腺癌患者接受雄激素去势治疗后患糖尿病的风险分析

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 5, 2015-09 ,pp. : 672-680

John Wiley & Sons Inc

Access to resources Recommend Favorite

Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate‐risk disease

By  

CANCER, Vol. 121, Iss. 16, 2015-08 ,pp. : 2713-2719

John Wiley & Sons Inc

Access to resources Recommend Favorite

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 9, 2015-06 ,pp. : 897-906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adverse effects of androgen‐deprivation therapy in prostate cancer and their management

By  

BJU INTERNATIONAL, Vol. 115, Iss. S5, 2015-04 ,pp. : 3-13

John Wiley & Sons Inc

Access to resources Recommend Favorite